logo

For the Inventor, By the Inventor

Millbrae, CA, United States of America

Yongmei Chen

This inventor holds 9 USPTO granted patents and 3 published patent applications. Top assignee: Genentech, Inc.. Active years: 2014-2021.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Yongmei Chen. Retrieved from https://idiyas.com/inventor/yongmei-chen-4noqr26f

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 9 

% Patents Active = 100.0

Average Co-Inventor Count = 6.7

ph-index = 2

Forward Citations = 13(Granted Patents)


Location History:

  • San Francisco, CA (US) (2014 - 2016)
  • Millbrae, CA (US) (2014 - 2018)
  • South San Francisco, CA (US) (2018 - 2021)

Company Filing History:

goldMedal9 out of 3,302 
 
Genentech, Inc.
 patents

Years Active: 2014-2021

Loading Chart...
9 patents (USPTO):Explore Patents
1. 10882921 - Host cell comprising nucleic acids encoding bispecific antibodies binding to beta-klotho and fibroblast growth factor receptor 1 and antibody production (2021-01-05),
2. 10246518 - Nucleic acids encoding bispecific antibodies binding to beta-Klotho and fibroblast growth factor receptor 1 (2019-04-02),
3. 9884919 - Methods of treatment with bispecific antibodies binding to beta-klotho and fibroblast growth factor receptor 1 (2018-02-06),
4. 9879094 - Nucleic acid molecules encoding for BACE1 antibodies (2018-01-30),
5. 9873748 - Bispecific antibodies binding to beta-klotho and fibroblast growth factor receptor 1 (2018-01-23),
6. 9512217 - Antibodies binding to IL-17A (2016-12-06),
7. 9453079 - Methods and compositions for neural disease immunotherapy (2016-09-27),
8. 8790642 - Cross-reactive and bispecific anti-IL-17A/F antibodies (2014-07-29),
9. 8772457 - BACE1 antibodies (2014-07-08),

Title: The Innovative Contributions of Yongmei Chen

Introduction

Yongmei Chen is a prominent inventor based in Millbrae, CA (US), known for her significant contributions to the field of biotechnology. With a total of 9 patents to her name, she has made remarkable advancements in the development of bispecific antibodies.

Latest Patents

Among her latest patents, Yongmei Chen has developed a host cell comprising nucleic acids encoding bispecific antibodies that bind to beta-klotho and fibroblast growth factor receptor 1. This innovative subject matter provides antibodies that bind to KLB and FGFR1, along with methods of utilizing these antibodies. In certain embodiments, her bispecific antibody binds to an epitope present on FGFR1 while also binding to an epitope present on KLB. Another notable patent includes nucleic acids encoding bispecific antibodies that serve the same purpose, further showcasing her expertise in this area.

Career Highlights

Yongmei Chen is currently employed at Genentech, Inc., where she continues to push the boundaries of scientific research and innovation. Her work has been instrumental in advancing therapeutic options in the biotechnology sector.

Collaborations

Yongmei has collaborated with notable colleagues such as Yan Wu and Scott Stawicki, contributing to a dynamic research environment that fosters innovation and discovery.

Conclusion

Yongmei Chen's contributions to biotechnology through her patents and collaborations highlight her as a leading inventor in her field. Her work continues to impact the development of new therapeutic solutions.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…